CONCORD, Calif.--(BUSINESS WIRE)--Feb. 23, 2006--Cerus Corporation (Nasdaq:CERS) today announced results for the fourth quarter and year-ended December 31, 2005. Revenues for the fourth quarter of 2005 were $5.6 million, up from $3.0 million for the fourth quarter of 2004, primarily due to amounts recognized in the current period from the amortization of past up-front payments from BioOne Corporation and MedImmune, Inc., for which revenue recognition was deferred, as well as from higher funding from the U.S. Armed Forces. Total operating expenses for the fourth quarter of 2005 were $9.0 million, up from $7.3 million for the same period in 2004, due primarily to increased preclinical activities associated with our immunotherapy programs.
